Skip to main content

UK MDx Shop Biofortuna Raises $1.6M, Feb 4, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK molecular diagnostics firm Biofortuna said this week it has raised £1 million ($1.6 million), which it will use to develop a market for its diagnostic genotyping products and new products.

The funding is being provided by EV Tech, Catapult Venture Managers, Alliance Fund Managers, and Biofortuna's non-executive directors.

Biofortuna is developing genotyping and antibody screening tests directed at organ transplantation and management, blood banking, disease identification, microbiology, and pharmacogenomics.

Mike Bunce, CEO of Liverpool-based Biofortuna, said in a statement that the funding will allow the company to "continue to develop our groundbreaking freeze dried diagnostic kits and consolidate our position as a unique global innovator in clinical diagnostics and lyophilisation techniques."

The company raised $1.6 million in May to commercialize its in vitro PCR kits for HLA genotyping and human disease diagnosis.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.